Evaluation of the safety and tolerability of a higher potency dose of varicella zoster virus vaccine live (Oka/Merck) among adults 50 years of age and older
Latest Information Update: 06 May 2022
At a glance
- Drugs Varicella zoster virus vaccine live (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme
- 12 May 2009 Actual completion date (Aug 2004) added as reported by ClinicalTrials.gov.
- 26 Feb 2007 Status changed from in progress to completed.
- 04 Nov 2005 New trial record.